All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sucroferric Oxyhydroxide
Therapeutic Area: Nephrology Product Name: Velphoro
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Details:
Clinical Kidney Journal published results from a real-world setting study, the VELREAL multicenter study, which showed a 20% decrease in serum phosphorus in addition to reduced parathyroid hormone level using Vifor Pharma’s Velphoro in CKD patients on dialysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
Details:
Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.